


## *Precision Medicine in Nephrology: Perspectives*

*Olivier Devuyst, MD, PhD*



*“The good physician treats the disease; the great physician treats the patient who has the disease”.*

Sir William Osler, 1903

### *2018: Era of precision (stratified) medicine*

- \* Using genetics and other “omics” as predictive tools to evaluate health risks
- \* Identifying patients with distinct mechanisms of disease and particular responses to treatments
- \* Define treatments that are effective for subgroups of patients




# Precision Medicine: Where are we ?

---

- Promise: to treat with a given drug only responders and patients not predisposed to toxicity.
- Very well developed in cancer medicine: successful precision medicine applications in breast, prostate, ovarian, colon and pancreatic cancer.
- Cardiovascular medicine, nephrology and hypertension lag behind oncology.

*Rare monogenic syndromes*: a single mutation explains the disease & dictates pharmacogenetics-led prescription:

- Liddle syndrome: R/ Amiloride
- Pseudohypoaldosteronism type II (Gordon syndrome):  
R/ Thiazide diuretics




# Cancer detection: Seeking signals in blood

Combining gene mutations and protein biomarkers for earlier detection and localization

## How the CancerSEEK algorithm works

Plasma-based sequencing of 16 cancer genes generates an Omega score that is combined with eight cancer-associated serum proteins to derive a probability for having any of eight different types of cancer. A machine learning algorithm then integrates these data with 31 additional serum proteins and patient gender to predict the tissue of origin.






# Insurance for broad genomic tests in oncology

Insurance coverage should precede rather than follow clinical validation of broad genomic testing in oncology

*“The line between clinical care and clinical investigation is shifting.”*

## The economic benefit of testing for somatic mutations in cancers

Without testing for mutation in the gene encoding the epidermal growth factor receptor (EGFR), all patients with lung adenocarcinoma would receive an 8-week trial of a drug targeting the EGFR and continue with treatment only if they showed an image-validated response. Patients in this 2010 study (19) whose tumors were found to have a mutation in the EGFR-encoding gene were treated with the targeted drug; the other patients were spared the costs and delay of an 8-week trial for a drug that would not work for them.



# MEDICINE'S FUTURE?

In an ambitious experiment, a rural U.S. health system is trying to integrate genomic screening into routine care



*“This is the future of health care.”*

**Michael Snyder,**  
Stanford Medicine's Center for  
Genomics and Personalized Medicine

## Pennsylvania's pioneering genomic medicine program


A half-million of Geisinger Health System's patients may have their DNA analyzed for disease mutations.

Geisinger informs patients of mutations in 76 genes solidly connected to various diseases.




## Cancer risk genes

Grouped by types of cancer or syndrome



## Cardiovascular risk genes

Grouped by condition or symptoms



## Other



SCIENCE

# *Precision Medicine: Challenges and Opportunities*

## Outline

- Insights from genetics - rare (kidney) diseases
- Use of genetic information - targeted treatments
- Insights from GWAS - risk of CKD, hypertension
- Perspectives for peritoneal dialysis

# *Precision Medicine: Challenges and Opportunities*


## Outline

- Insights from genetics - rare (kidney) diseases
- Use of genetic information - targeted treatments
- Insights from GWAS - risk of CKD, hypertension
- Perspectives for peritoneal dialysis



# Falling fast

In the first few years after the end of the Human Genome Project, the cost of genome sequencing roughly followed Moore's law, which predicts exponential declines in computing costs. After 2007, sequencing costs dropped precipitously.



# Next-generation Sequencing: Impact for Rare Diseases


---

- Development and validation of **multigene panels**: *simultaneous investigation of all relevant genes for a given phenotype*
  - Reduced costs and turn-around times
- Successful application **multigene panels/NGS for diagnostic**:
  - Alport syndrome
  - Steroid-resistant nephrotic syndrome
  - Nephronophthisis - ciliopathies
  - Tubulopathies

## Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies

- *These results demonstrate a high diagnostic yield of genetic testing in children with a clinical diagnosis of renal tubulopathy.*
- *Genetic testing established a definitive diagnosis in almost two-thirds of patients - informing prognosis, management and genetic counseling.*

# Renal Fanconi Syndrome: Rare Disorders Targeting the Endolysosomal System






**Mutation Update of the *CLCN5* Gene Responsible for Dent Disease 1**



- 234 mutations
- 170 families



Type of mutation (n=234)

- C
- ▼ Missense (33.33%)
  - Frameshift (29.05%)
  - ◆ Nonsense (17.52%)
  - ★ Splicing (12.39%)
  - Large deletion (4.70%)
  - Inframe (2.56%)
  - ☆ Other (Alu insertion) (0.42%)
  - ▽ Novel mutations



De novo mutation rate  
~ 10%

# Dent Disease: Renal Fanconi Syndrome & Kidney Stones

• Low-molecular-weight proteinuria	100%
• Albuminuria	100%
• Aminoaciduria	100%
• Glucosuria	8/15
• Rickets	6/15
• Hypercalciuria	12/13
• Kidney stones	8/15
• Nephrocalcinosis	11/15
• Renal failure	11/15
• Impaired urinary concentration	9/9
• Acidification defect	7/14

# Dent Disease: Phenotype Heterogeneity

---

*Clinical data from 377 male patients belonging to 334 families*

- **Micro or macrohaematuria** (n = 71)
- Polyuria/polydipsia (31/43)
- **Proteinuria** (n = 57): median value 1.28 g/24 hr
- **Proteinuria in the nephrotic range** (n = 13)
- **Enuresis** (n = 5)
- **Hypomagnesaemia** (4/30)
- **Night blindness** responsive to vitamin A

→ *New phenotypes: specific management and treatment*

# *Precision Medicine: Challenges and Opportunities*

## Outline

- Insights from genetics - rare (kidney) diseases
- **Use of genetic information - targeted treatments**
- Insights from GWAS - risk of CKD, hypertension
- Perspectives for peritoneal dialysis




# Autosomal Dominant Polycystic Kidney Disease

---

- Most frequent inherited nephropathy (1:400 - 1:1,000)
- Enlarged kidneys, multiple cysts < tubules
- Responsible for 4 - 10% of patients on dialysis - transplantation




# Exponential Progression of Cysts -Kidney Volume in ADPKD






# Inter- and Intra-familial Variability in ADPKD: A Multicentric Sib-pair Study

Age at ESRD (years)




# Molecular Basis of ADPKD: Mutations in *PKD1* and *PKD2*





## Type of *PKD1* Mutation Influences Renal Outcome in ADPKD



Genkyst: 741 patients from 519 pedigrees




EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

ORIGINAL ARTICLE

## Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, M.D., Ph.D., Arlene B. Chapman, M.D.,  
Olivier Devuyst, M.D., Ph.D., Ron T. Gansevoort, M.D., Ph.D.,  
Jared J. Grantham, M.D., Eiji Higashihara, M.D., Ph.D., Ronald D. Perrone, M.D.,  
Holly B. Krasa, M.S., John Ouyang, Ph.D., and Frank S. Czerwiec, M.D., Ph.D.,  
for the TEMPO 3:4 Trial Investigators\*

N Engl J Med. 2012; 367: 2407-18



27/02/2015

### Jinarc recommended for approval in ADPKD

The EMA has recommended granting a marketing authorisation to Jinarc (tolvaptan). Jinarc is indicated to slow the progression of cyst development and failing kidney function in adult patients with ADPKD.

**Jinarc is for use in patients with normal to moderately reduced kidney function who have rapidly progressing ADPKD.**

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

*Who should benefit from the treatment ?*

Rapid progressors:

- Historical renal function decline  $> 5 \text{ ml/min/1.73m}^2/\text{yr}$  (or  $2.5 \text{ ml/min} / 5 \text{ yr}$ )
- Historical TKV progression  $> 5\% / \text{yr}$
- Mayo class 1C-1E (HTKV, age)
- Truncating *PKD1* mutation and early clinical symptoms – Pro-PKD score  $>6$
- Patients with a family history of ESRD before age 55 years


# *Precision Medicine: Challenges and Opportunities*

## Outline

- Insights from genetics - rare (kidney) diseases
- Use of genetic information - targeted treatments
- **Insights from GWAS - risk of CKD, hypertension**
- Perspectives for peritoneal dialysis




# Genetic Architecture of Disease



# A decade of shared genomic associations

*Big data !*



- Surprising associations: e.g. Complement Factor H gene and blindness (*Science* 2005)
- Less than 10% of associations lie in protein-coding regions of the genome
- Specific regions associated with multiple, seemingly separate diseases

## MEDICAL RESEARCH

# Genome studies attract criticism

*Geneticists question ability of genome-wide association studies to find useful disease links.*


In a paper published in *Cell* on 15 June, Pritchard and two other geneticists suggest that **many GWAS hits have no specific biological relevance to disease** (Boyle EA et al. *Cell* **169**, 2017). Rather, these 'peripheral' variants probably act through complex biochemical regulatory networks to influence the activity of a few 'core' genes that are more directly connected to an illness.

*Challenge in genomics: collecting ever more genetic associations over understanding the biology behind them.*

# Multiple loci associated with indices of renal function and chronic kidney disease


Anna Köttgen<sup>1,25</sup>, Nicole L Glazer<sup>2,25</sup>, Abbas Dehghan<sup>3,24,25</sup>, Shih-Jen Hwang<sup>4,25</sup>, Ronit Katz<sup>5</sup>, Man Li<sup>1</sup>, Qiong Yang<sup>6</sup>, Vilmundur Gudnason<sup>7,8</sup>, Lenore J Launer<sup>9</sup>, Tamara B Harris<sup>9</sup>, Albert V Smith<sup>7</sup>, Dan E Arking<sup>10</sup>, Brad C Astor<sup>1</sup>, Eric Boerwinkle<sup>11</sup>, Georg B Ehret<sup>10,12</sup>, Ingo Ruczinski<sup>13</sup>, Robert B Scharpf<sup>13</sup>, Yii-Der Ida Chen<sup>14</sup>, Ian H de Boer<sup>15</sup>, Talin Haritunians<sup>14</sup>, Thomas Lumley<sup>5</sup>, Mark Sarnak<sup>16</sup>, David Siscovick<sup>17</sup>, Emelia J Benjamin<sup>18</sup>, Daniel Levy<sup>4</sup>, Ashish Upadhyay<sup>19</sup>, Yurii S Aulchenko<sup>3</sup>, Albert Hofman<sup>3</sup>, Fernando Rivadeneira<sup>20</sup>, André G Uitterlinden<sup>20</sup>, Cornelia M van Duijn<sup>3</sup>, Daniel I Chasman<sup>21</sup>, Guillaume Paré<sup>21</sup>, Paul M Ridker<sup>21</sup>, W H Linda Kao<sup>1</sup>, Jacqueline C Witteman<sup>3,24,26</sup>, Josef Coresh<sup>1,13,26</sup>, Michael G Shlipak<sup>22,26</sup> & Caroline S Fox<sup>4,23,26</sup>

VOLUME 41 | NUMBER 6 | JUNE 2009 NATURE GENETICS




*UMOD* locus: First discovered in association with eGFR<sub>crea</sub> in EU ancestry, associated with CKD at genome-wide significant level

# UMOD is Standing among Genetic Loci for CKD



# The *UMOD* Risk Allele: Increased Urinary Uromodulin





Each copy of the **risk (G) allele** of rs12917707 is associated with a significant ***increase in urinary uromodulin*** levels



I. Tamm & F. Horsfall 1952 – D. Pennica 1987

*Tamm-Horsfall protein - uromodulin:*  
*the most abundant protein in normal human urine (50-100 mg/day)*



RNAs isolated from 150 different tissues and cell lines:  
uromodulin mRNA detected **only from the kidney.**






Biomarker value of uromodulin ?

# Associations of Urinary Uromodulin with Clinical Characteristics and Markers of Tubular Function in the General Population

*Clin J Am Soc Nephrol.* 11, 2016

Menno Pruijm, Belen Ponte, Daniel Ackermann, Fred Paccaud, Idris Guessous, Georg Ehret, Antoinette Pechère-Bertschi, Bruno Vogt, Markus G. Mohaupt, Pierre-Yves Martin, Sonia C. Youhanna, Nadine Nägele, Peter Vollenweider, Gérard Waeber, Michel Burnier, Olivier Devuyst, and Murielle Bochud



Uromodulin levels correlate with eGFR, kidney length/mass and tubular activity

see commentary on page 944

## Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults

Pranav S. Garimella<sup>1</sup>, Mary L. Biggs<sup>2</sup>, Ronit Katz<sup>3</sup>, Joachim H. Ix<sup>4</sup>, Michael R. Bennett<sup>5</sup>, Prasad Devarajan<sup>5</sup>, Bryan R. Kestenbaum<sup>6</sup>, David S. Siscovick<sup>7</sup>, Majken K. Jensen<sup>8</sup>, Michael G. Shlipak<sup>9</sup>, Paulo H.M. Chaves<sup>10</sup> and Mark J. Sarnak<sup>1</sup>

- uUMOD in 192 participants of the Cardiovascular Health Study with over a 30% decline in estimated glomerular filtration rate (eGFR) over 9 years, 54 with incident end-stage renal disease (ESRD), and in a random subcohort of 958 participants.
- In a case–control study evaluating eGFR decline, each 1-s.d. higher uUMOD was associated with a 23% lower odds of eGFR decline (odds ratio 0.77 (95% CI 0.62–0.96)) and a 10% lower risk of mortality (hazard ratio 0.90 (95% CI 0.83–0.98)) after adjusting for demographics, eGFR, albumin/creatinine ratio, and other risk factors.

*Low uUMOD levels identify persons at risk of progressive kidney disease and mortality.  
Higher levels of uromodulin – protective !*



---

# Association of Preoperative Urinary Uromodulin with AKI after Cardiac Surgery

Pranav S. Garimella,\* Bertrand L. Jaber,<sup>†</sup> Hocine Tighiouart,<sup>\*§</sup> Orfeas Liangos,<sup>||</sup> Michael R. Bennett,<sup>¶</sup>  
Prasad Devarajan,<sup>¶</sup> Tarek M. El-Achkar,<sup>\*\*</sup> and Mark J. Sarnak\*

*Clin J Am Soc Nephrol* 12: 10–18, 2017.

- A post hoc analysis of a prospective cohort study of 218 adults undergoing on-pump cardiac surgery to evaluate the associations of preoperative urinary uromodulin with postoperative AKI
- Lower urinary uromodulin associated with higher odds for AKI (OR, 1.49 per 1-SD lower uromodulin; 95% CI, 1.04 to 2.13), marginally attenuated after adjustment.
- The lowest uromodulin-to-creatinine ratio quartile was also associated with higher odds for AKI relative to the highest quartile (odds ratio, 2.94; 95% CI, 1.19 to 7.26).

*Lower uromodulin-to-creatinine ratio is associated with higher odds of AKI  
Higher levels of uromodulin – protective !*

## Urinary Uromodulin and Risk of Urinary Tract Infections: The Cardiovascular Health Study

Pranav S. Garimella, MD, MPH,<sup>1</sup> Traci M. Bartz, PhD,<sup>2</sup> Joachim H. Ix, MD, MAS,<sup>3</sup>  
Michel Chonchol, MD,<sup>4</sup> Michael G. Shlipak, MD, MPH,<sup>5</sup> Prasad Devarajan, MD,<sup>6</sup>  
Michael R. Bennett, PhD,<sup>6</sup> and Mark J. Sarnak, MD, MS<sup>1</sup>

- **Prospective longitudinal cohort** study in 953 participants enrolled in the Cardiovascular Health Study.
- Predictive value of **urinary uromodulin on composite of outpatient UTI events** adjusted for age, race, sex, body mass index, diabetes, eGFR, UAE.
- Persons in the **highest quartile of uromodulin** concentration had a **significantly lower risk for UTIs** (incidence rate ratio [IRR], 0.47; 95% CI, 0.29-0.79) compared with those in the lowest quartile.
- Conclusions: **High urinary uromodulin levels are associated with lower risk for UTI** in older community-dwelling adults independent of traditional UTI risk factors.

→ *This finding supports a protective role of uromodulin against UTI.*





# *Precision Medicine: Challenges and Opportunities*

## Outline

- Insights from genetics - rare (kidney) diseases
- Use of genetic information - targeted treatments
- Insights from GWAS - risk of CKD, hypertension
- Perspectives for peritoneal dialysis

# Precision Medicine in PD: Peritoneal Equilibration Test




■ Low  
■ L Ave  
■ H Ave  
■ High

*Biological parameter influencing dialysate prescription*

Twa	Peritoneal solute transport	Drain volume	Predicted long-term response to standard-dose CAPD or CCPD <sup>a</sup> after loss of residual renal function		Preferred dialysis prescription after loss of residual renal function
			ultrafiltration	dialysis	
	High	low	poor	adequate	NIPD, DAPD <sup>b</sup>
	High average	low average	adequate	adequate	standard-dose PD <sup>a</sup>
	Low average	high average	good	adequate or inadequate <sup>c</sup>	standard-dose PD <sup>a</sup> high-dose PD <sup>d</sup>
	Low	high	excellent	inadequate	high-dose PD <sup>d</sup> or hemodialysis <sup>e</sup>

# The Peritoneal Membrane as Model for Transport




Mesothelium

Interstitium



**Capillary endothelium**  
*Main functional barrier to solute & fluid transport*

# Overton : Water Pores in Cell Membranes



**Osmotic Gradient**




# Structure of Aquaporins



***AQP1 tetramers: 3 billions of water molecules per second***



# Peritoneal Dialysis in *Aqp1* Knockout Mice




- *AQP1* pores mediate 50% of UF
- *AQP1* pores mediate sodium sieving
- Dose-effect: Heterozygous mice



## *Genetics - Useful for Peritoneal Dialysis ?*




# Distribution of Water Transport in PD Patients





*Clinical variables account for only ~ 20% of the variability:  
→ Genetic Influence ?*

# AQP1 Haplotype: Frequent Promoter Variants





# The AQP1 Promoter Variant: Influences Water Transport and Outcome during PD

The TT variant of rs2075574 - decreased AQP1 gene expression in peritoneal microvasculature



Water transport in human erythrocytes and across the peritoneal membrane




Outcome:  
*Patient & technique survival*



# Unbiased Approach: Bio-PD Study GWAS to Identify Loci Influencing Peritoneal Transport

- Multicentric: USA & Europe
- Large discovery and replication cohorts (n = 1536 and 1696 patients); Illumina Omni 2,5M
- Traits: solute & water transport in PD





Coordinator: Raj Mehrotra




## Conclusions - Take Home Messages






# Kidney Disorders: Multi-omics Technologies



# “Biomarking” the transition from genetic risk to kidney disease



Identifying individuals with high-risk APOL1 genotype, at increased risk for CKD. Only some individuals harboring APOL1 high-risk genotype (pink figure, left column) will go on to develop CKD. Clinical risk factors as well as biomarkers would help in identifying the individuals who are more prone to develop CKD (red figure, right column). Clinical intervention to reduce these risk factors (e.g., HIV treatment, avoiding interferon treatment, and consultation regarding the risk of kidney donation) would reduce the risk for CKD progression (pink figure, right column). Adding biomarkers, such as soluble urokinase plasminogen activating receptor (SuPAR), tumor necrosis factor receptor  $\frac{1}{2}$  (TNFR1/2), and kidney injury molecule-1 (KIM1) to the risk stratification should improve clinical trial design and hopefully translate to reduced renal events.

*Merci pour votre attention*

## Precision medicine study launches

**BIOMEDICINE | The U.S. National Institutes of Health** detailed its plans to open national enrollment for a massive study of personalized medicine on 6 May, with a goal of enlisting 1 million people.

The All of Us project will explore links between genes, lifestyle, and disease by following participants' health for 10 years.

Participants will be asked to share their electronic medical records, and some will be invited to give blood and urine samples and wear a Fitbit-like device that gathers health data.



# Acknowledgements

## UZH, Zurich

H. Debaix, N. Nagele  
E. Olinger, H. Belge, A. Luciani, B. Festa  
B. Glaudemans, J. Loffing

## San Raffaele Institute, Milan

L. Rampoldi, M. Trudu  
I. Bernascone, C. Schaeffer  
P. Manunta MP. Rastaldi

## UCL, Brussels

Y. Pirson, M. Jadoul, E. Goffin, J. morelle  
L. Labriola, K. Dahan  
Y. Cnops, S. Druart

## Univ. Ferrara

G. Barbujani

## Université de Lausanne

M. Bochud, O. Bonny, P. Vollenweider  
COLAUS & SKIPOGH Investigators

## MRC- University of Edinburgh

N. Hastie, C. Hayward

## NIH, NHLBI

C. Fox, M. Olden

## Univ. Tennessee





D.S. Hains

## ETH Zurich

R. Glockshuber, M. Aebl



# The 3-Pore Model: Endothelium as a Functional Barrier in PD



Accumulating evidence has suggested that many causal GWAS variants might be common regulatory variants. Efforts to re-sequence disease-associated genes identified in GWAS, such as UMOD for eGFR<sup>27</sup>, and PLA2R1 in MN48, have failed to identify common or rare missense variants that could explain the observed GWAS signals either individually or in combination.

Instead, the latest GWAS meta-analysis from the CKDGen Consortium reported that eGFR-associated variants and/or their proxies map into regions with regulatory potential more often in kidney tissues than in a set of control tissues<sup>19</sup>. This observation is further supported by a study linking eGFR-associated SNPs to transcript expression in different renal tissues<sup>28</sup>.

More generally, a large 2015 study by the Genotype- Tissue Expression Project linked genetic variation to gene expression across a variety of human tissues and found that SNPs that are associated with transcript levels (also called expression quantitative trait loci (eQTL)) are enriched for GWAS SNPs, with the tissue often matching the pathophysiology of the disease under study<sup>70</sup>.

This report, which does not include data from kidney tissue, also presents selected examples of GWAS signals that can be explained by eQTLs. In the field of kidney disease, variants in the UMOD gene region, identified in GWAS of eGFR, modulate CKD risk by altering the expression of the UMOD transcript.

An exception is APOL1, for which the causal variants are coding and directly affect protein sequence.

[Hypertension](#). 2014 Nov;64(5):918-23.

**Uromodulin, an emerging novel pathway for blood pressure regulation and hypertension.**

[Padmanabhan S](#)<sup>1</sup>, [Graham L](#)<sup>2</sup>, [Ferreri NR](#)<sup>2</sup>, [Graham D](#)<sup>2</sup>, [McBride M](#)<sup>2</sup>, [Dominiczak AF](#)<sup>2</sup>.

### **Future Perspectives**

GWAS discovery followed by functional validation has resulted in renewed interest in *UMOD* and its role in BP regulation. These early functional data while promising highlights the importance of further work that needs to be prioritized to elucidate the underpinning molecular mechanisms. Some of the crucial questions that need to be investigated include the role of uromodulin in maintaining water impermeability in TAL; the effect of uromodulin on NKCC2, macula densa, tubuloglomerular feedback, distal sodium transporters, renin–angiotensin–aldosterone system; and whether immune mechanisms play a role in BP regulation by uromodulin. More importantly, further research in these areas will enable development of a therapeutic application (either novel drug or repurposing an existing drug or a screening diagnostic) for targeted treatment. This is crucial because despite major advances in cardiovascular health, hypertension remains the risk factor contributing most to the overall burden of disease globally and there is a paucity of novel antihypertensive drugs in clinical trials or pharmaceutical development pipeline. More fundamentally, the uromodulin story highlights the power of GWAS in identifying novel pathways of disease.

Precision medicine – blended model see Circulation figure



OUTLOOK  
Climate  
change

# nature

THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

## BEING HUMAN

Cataloguing the effects of genetic variation on gene expression  
in healthy tissues PAGES 190, 204, 239, 244 & 249

BUSINESS

### PERSONAL GENETICS

*The turbulent story  
of 23andMe*

PAGE 174

POLITICS

### STAR LAWS

*Time to update the Outer  
Space Treaty*

PAGE 182

ENGINEERING

### MOLTEN - METAL MACHINE

*Ceramic pump handles liquid  
metals at record temperatures*

PAGES 194 & 199


NATURE.COM/NATURE

12 October 2017

Vol 550, No. 7675


# Cracking the regulatory code

A collection of papers catalogues the associations between genetic variation and gene expression in healthy tissues — the largest analysis of this kind so far. [SEE ARTICLE P.204 & LETTERS P.239, P.244 & P.249](#)



Data collection by the Genotype-Tissue Expression (GTEx) Consortium. The consortium 1–4 collected tissue samples from 44 tissues in 449 human individuals. The researchers analysed these samples to look for genetic differences between individuals — in this example, one individual harbours two adenosine bases (As) at a particular point on two sister chromosomes, another harbours one A and one guanine (G), and a third harbours two Gs. The authors measured RNA levels to determine whether such genetic variation was associated with differences in gene expression (here, in the levels of RNA transcribed from gene X). *Different genetic variants were associated with different expression in different tissues.*







Summary of the 44 tissues and 7,051 samples used for eQTL analyses from the GTEx v6p release.

## Uromodulin – FimH dynamic Interaction:

- Purification of uromodulin, *UMOD* genotypes
- FimH/uromodulin complex (SEC, SDS-PAGE): N of FimH binding per monomer
- Binding stoichiometry, Rate of dissociation from FimH
- Influence of glycosylation patterns, modulation by NaCl, urea, ...



The NEW ENGLAND  
JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 19, 2014

VOL. 370 NO. 25

Antimicrobial Prophylaxis  
for Children with Vesicoureteral Reflux



The RIVUR Trial Investigators\*

*2-yr, multisite prospective cohort to identify risk factors for recurrent UTIs  
in children aged 2- 70 months*

- RIVUR: randomized intervention for VUR, N=305
- CUTIE: careful UTI evaluation - without VUR, N=195
- Female, 90%; Caucasians, 75%; *E. coli*, 90%; febrile & symptomatic UTIs, 50%




# Effect of *UMOD* Genotype on Recurrence of UTI in Children




*Excess of CC allele (low uromodulin) in children with recurrent UTIs without VUR*

# *Uropathogenic E. coli* : Type-1 Fimbriae




- Highly stable, multi-protein complexes
- Required for bacterial attachment to glycoprotein receptor uroplakin – urothelial cells
- Virulence factor



# Algorithm to assess indications for treatment in ADPKD

- CKD stage and age
- History: eGFR, TKV, family
- Scores



Other associations of the UMOD locus:

Risk of hypertension and incident CVD in extreme case-control study

Global BPGen consortium

Reduced risk of kidney stones


combined Dutch and Icelandic sample

Urinary levels of uromodulin

Meta-analysis – 10,884 individuals EU descent

GWAS of blood pressure extremes, which identified variants in the uromodulin gene (UMOD) associated with hypertension. The special feature of this study was the selection of 2000 so called hypercontrols, subjects who had BP below 120/80 mmHg and were free from cardiovascular events during 10 year follow-up

XIX  
XX  
XXI



1873 Roviada describes cilindrina, a wax-like substance in kidney tubules.

1950: Tamm and Horsfall isolate an abundant mucoprotein from normal urine.

1950-1980: Tamm-Horsfall protein is shown to be the most abundant protein in mammalian urine, forming large aggregates.

1987: Uromodulin is identical to Tamm-Horsfall protein, and only detected in kidney.

1985, Uromodulin purified from the urine of pregnant women. Marked immunoregulatory activity *in vitro*.

2004: *Umod* KO mice show higher propensity for kidney stones and urinary tract infections, and altered tubular salt handling.

2002-2003: Rare mutations in *UMOD* cause ADTKD, associated with intracellular protein retention (ER storage disease).

2005: Uromodulin linked to innate and adaptive immunity in urinary tract.

2009: GWAS identify common *UMOD* variants strongly associated with eGFR<sub>crea</sub> and CKD in the general population

2010: Association of *UMOD* variants with hypertension.

2011: Uromodulin regulates NKCC2 and ROMK in TAL.

2013-14: *UMOD* risk variants directly increase uromodulin expression and secretion leading to salt-sensitive hypertension and kidney damage.

2016: Large meta-analysis for eGFR and CKD demonstrating the predominant size effect of the *UMOD* locus.

2016: Identification of pathogen-driven selection at the *UMOD* locus, potentially due to protection against UTI in various populations.

2016: Serum uromodulin levels correlate with renal function.

2016: Population-based studies demonstrating that uromodulin urinary levels correlate with functioning nephron mass and tubular function parameters.

2015-2017: Predictive value of urine and serum uromodulin levels.

# Clinical, Genetic, and Urinary Factors Associated with Uromodulin Excretion

*Stéphan Troyanov,\* Catherine Delmas-Frenette,\* Guillaume Bollée,<sup>†</sup> Sonia Youhanna,<sup>‡</sup> Vanessa Bruat,<sup>§||</sup> Philip Awadalla,<sup>§||</sup> Olivier Devuyst,<sup>‡</sup> and François Madore\**

**Table 3. Multivariate predictors of uromodulin**

Variables	Standardized- $\beta$	<i>P</i> Value
GFR (CKD-EPI; ml/min per 1.73 m <sup>2</sup> )	0.11	0.001
rs4293393 (TT compared with CC with CT)	0.07	0.04
rs12446492 (TT compared with AA with AT)	0.09	<0.01
FE-Na	0.10	<0.01
Presence of glycosuria	-0.07	0.02
FE-Ua	0.29	<0.001
Use of uricosuric drugs	-0.07	0.02




## Updates in renal medicine 2

# Autosomal dominant polycystic kidney disease: the changing face of clinical management

Lancet 2015; 385: 1993–2002

Albert CM Ong, Olivier Devuyst, Bertrand Knebelmann, Gerd Walz, on behalf of the ERA-EDTA Working Group for Inherited Kidney Diseases\*



## The Two Faces of *UMOD*






Complex diseases; GWAS  
CKD, hypertension

Monogenic, rare diseases  
ADTKD-*UMOD*

Original Article


Determination of uromodulin in human urine: influence of storage and processing



**Table 1. Comparison of the characteristics of the in-house ELISA for uromodulin and the commercially available ELISA kits**

Kit	Detection range (standard curve) (ng/mL)	Inter-assay variability (%)	Intra-assay variability (%)
In-house	3.9–500	3.28	5.46
MD Bioproduct (Cat. M036020)	2.34–150	11.63	8.36
BioVendor (Cat. RD191163200R)	0.5–32	6.4	2
USCN Life Science, Inc. (Cat. E96918 Hu)	3.13–200	<12	<10


# Mechanism of Cyst Formation in ADPKD



Proliferation – Dedifferentiation - Fluid secretion









# Uromodulin Mutations in ADTKD/FJHN



→ 125 mutations, 95% cluster in exons 3 and 4  
 → 121/125 missense mutations, 4 in-frame deletions  
 → Conserved sequence, **cysteine residues (78/125)**

# Uromodulin Overexpression: Kidney Damage

Tg *Umod* Mice





# Research Programmes, Cohorts, Biorepositories

---

*Fragmentation of patient-related information represents a major obstacle for rare disease research.*

- **EPIRARE**: European Platform for Rare Disease Registries ([www.epirare.eu](http://www.epirare.eu))
- **PARENT**: Patient Registries Initiative ([www.patientregistries.eu](http://www.patientregistries.eu))
- **RD-CONNECT**: A platform connecting databases, registries, biobanks
- **IRDIRC**: International Rare Diseases Research Consortium ([www.irdic.org](http://www.irdic.org))
- **EURenOmics**: EU Consortium for High-Throughput Research in Rare Kidney Diseases
- **ORPHANET**: The portal for rare diseases and orphan drugs ([www.orpha.net](http://www.orpha.net))
- **EURORDIS**: The European Organization for Rare Diseases ([www.eurordis.org](http://www.eurordis.org))
- **Center for Mendelian Genomics** ([www.mendelian.org](http://www.mendelian.org))
- ...


# The *UMOD* locus stands out among all loci

---

- \* First discovered in association with eGFR<sub>crea</sub> & CKD in EU ancestry  
(Köttgen 2009)
- \* Largest effect size on both eGFR and CKD risk
- \* Consistency of effect among different ethnic groups
- \* Relationship with age: effect very significant after age 60 years
- \* Only locus associated with incident CKD (OR 1.3 with each copy of risk allele)


All eGFR<sub>crea</sub> loci account for 4% of variance: *UMOD* >1%  
i.e. 25% of eGFR<sub>crea</sub> variability explained by genetic factors

# Innate Immune Response: Principal Mechanism of Defense against UTI



## ***Uromodulin defense against UPEC:***

- Limits attachment to uroplakin receptors
- Promotes dendritic cell maturation via TLR4
- Activates innate & adaptive immunity
- Danger signal - dendritic cells – inflammasome



## **Preoperative levels of urinary uromodulin predict acute kidney injury after pediatric cardiopulmonary bypass surgery**

Michael R. Bennett<sup>1</sup> · Olivia Pyles<sup>1</sup> · Qing Ma<sup>1</sup> · Prasad Devarajan<sup>1</sup>

One hundred and one children undergoing CPB were enrolled. Urine was collected prior to CPB, and AKI was defined as  $\geq 50\%$  increase in serum creatinine from preoperative baseline within 48 h of surgery.


Forty-seven patients (47%) developed AKI, and 92% of participants in the lowest quartile of preoperative uUMOD concentrations developed AKI compared with 8% in the highest quartile.

Children with lowest preoperative levels of uUMOD have greatly increased risk of AKI post-CPB. If uUMOD were used to risk-stratify patients undergoing CPB, clinical measures could be taken to minimize AKI development.

## ARTICLES


# Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

The Wellcome Trust Case Control Consortium\*




- Wellcome Trust Case Control Consortium, 50 groups in UK
- Seven diseases (2'000 cases each) compared to 3'000 controls
- 24 loci in 6 traits – none for hypertension



# TAL: Uromodulin Regulates NKCC2 and ROMK



a




rbTAL cells: effect of THP on pNKCC2



*Xenopus* oocytes: ROMK currents/surface



# Monogenic kidney disease genes map into GWAS loci



→ Indicates a continuum between rare disruptive mutations and common regulatory variants in genes that are important for kidney development and function.



## Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—A KDIGO consensus report



Kai-Uwe Eckardt<sup>1</sup>, Seth L. Alper<sup>2</sup>, Corinne Antignac<sup>3,4</sup>, Anthony J. Bleyer<sup>5</sup>, Dominique Chauveau<sup>6</sup>, Karin Dahan<sup>7</sup>, Constantinos Deltas<sup>8</sup>, Andrew Hosking<sup>9</sup>, Stanislav Knoch<sup>10</sup>, Luca Rampoldi<sup>11</sup>, Michael Wiesener<sup>1</sup>, Matthias T. Wolf<sup>1,2</sup> and Olivier Devuyst<sup>13</sup>

**Table 1 | New gene-based classification and terminology of different types of ADTKD**

Causal Gene	Proposed terminology	Previously used terminology
<i>UMOD</i>	ADTKD- <i>UMOD</i>	UKD (Uromodulin Kidney Disease) <sup>a</sup> UAKD (Uromodulin-Associated Kidney Disease) FJHN (Familial Juvenile Hyperuricemic Nephropathy) MCKD2 (Medullary Cystic Kidney Disease type 2)
<i>MUC1</i>	ADTKD- <i>MUC1</i>	MKD (Mucin-1 Kidney Disease) <sup>a</sup> MCKD1 (Medullary Cystic Kidney Disease type 1)
<i>REN</i>	ADTKD- <i>REN</i>	FJHN2 (Familial Juvenile Hyperuricemic Nephropathy type 2)
<i>HNF1B</i>	ADTKD- <i>HNF1B</i>	MODY5 (Maturity-Onset Diabetes mellitus of the Young type 5) RCAD (Renal Cyst and Diabetes Syndrome)


Consensus for a single clinical entity: **ADTKD - 4 genes**

# Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)



- Hyperuricemia (low FEurate) during childhood
- Tubulointerstitial nephritis (thickening TBM)
- Progressive renal failure - adulthood



# Exponential Progression of TKV in ADPKD: CRISP



TKV measured  
by MRI



## Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials



eGFR decline in 538 ADPKD patients from Mayo, with TKV imaging

# Mayo Classification Score

## CLASSIFICATION OF TYPICAL ADPKD CALCULATOR


- Total kidney volume: mL
- Height: m
- Age: yrs

→ *Height-adjusted TKV*

→ *ADPKD classification*



# The Mayo Clinic classification



# Autosomal Dominant Polycystic Kidney Disease



- **Hypertension:** early – almost always
- **Bleeding:** 50 % of cases
- **Kidney stone:** 20 % of cases
- **Cyst infection:** 10 % of cases
- **Renal failure:** 75% of cases

*NDT Perspectives*

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

*Who should benefit from the treatment ?*


# Recommendations for the use of tolvaptan in ADPKD

Tolvaptan can be prescribed to adult ADPKD patients aged <50 years with CKD stages 1 to 3a.

## Rapid progressors:


- Historical renal function decline  $> 5 \text{ ml/min/1.73m}^2/\text{yr}$  (or  $2.5 \text{ ml/min} / 5 \text{ yr}$ )
- Historical TKV progression  $> 5\% / \text{yr}$
- Mayo class 1C-1E (HTKV, age)
- Truncating *PKD1* mutation and early clinical symptoms – Pro-PKD score  $>6$
- Patients with a family history of ESRD before age 55 years

# Genetic Architecture of Kidney Disease



# Uromodulin:

## A multi-faceted protein in the urinary tract






# Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD

Böger CA, Gorski M, Li M, Hoffmann MM, Huang C, et al.

September 2011 | Volume 7 | Issue 9 | e1002292



- *UMOD* is associated with incident CKD at a genome-wide significant level  
→ OR of 1.3 per copy of risk allele
- *UMOD* is also associated with incident ESRD

# The *UMOD* Risk Allele Increases Urinary Uromodulin






Each copy of the **risk (G) allele** of rs12917707 results in a significant *increase in urinary uromodulin* levels

# Genetic studies: healthy individuals




# Observational epidemiological studies


**Organ level:** Biomarker for kidney health




**Cellular level:** Susceptibility CKD (GWAS)




**Genetic studies:**  
healthy individuals



**Organ level:** Biomarker for kidney health





**Cellular level:** Susceptibility CKD (GWAS)





## Observational epidemiological studies

**Cross-sectional studies  
healthy subjects**





**Prospective studies  
risk subjects (aged, early CKD)**




## Genetic studies: healthy individuals

**UMOD  
genetic makeup**





# Causality of Uromodulin levels? Mendelian Randomization




The three principles of instrumental variable analysis are:


1. the instrumental variable (a genetic variant here) must associate with the exposure
2. the instrumental variable must not associate with confounders that are either known or unknown (U)
3. there is no pathway from the SNP to disease that does not include the exposure of interest.

# Observational epidemiological studies



**Organ level:** Biomarker for kidney health





**Cellular level:** Susceptibility CKD (GWAS)




**Cross-sectional studies**  
healthy subjects




**Prospective studies**  
risk subjects (aged, early CKD)




## Genetic studies: healthy individuals




## A proposed Mendelian randomization study



# Uromodulin in TAL Segment



- Handling of NaCl:
  - Blood pressure
  - Urinary concentration
  - Loop diuretics
- Handling of Ca<sup>2+</sup> & Mg<sup>2+</sup>:
- Secretion of uromodulin
  - Local & downstream effects





- 640 AA, 48 cysteines (24 S-S), 7 N-glycosylation (25-30% carbohydrate content)
- GPI - Proteolytic cleavage → urine excretion & polymerisation → filaments

## ***In vitro* binding of type 1-fimbriated *Escherichia coli* to uroplakins Ia and Ib: Relation to urinary tract infections**

(epithelial differentiation/urothelium/bladder epithelium/receptor)

XUE-RU WU\*†‡§, TUNG-TIEN SUN¶||\*\*, AND JUAN J. MEDINA\*



- Highly stable, multi-protein complexes
- Required for bacterial attachment to glycoprotein receptor uroplakin – urothelial cells
- Virulence factor

—●— high mannose glycan;  
—■— complex type glycan;  
■ peptide backbone of monomeric THP;

COLAUS (N=2,497) - General Population Cohort:  
**Uromodulin Inversely Associated with Nitrites in Urine**

**Table 4.** Multiple logistic regression for factors associated with the presence of urinary nitrites in the CoLaus study

Parameter (N=2497)	Odds Ratio	95% Confidence Interval	P Value
Age (yr)	1.04	1.02 to 1.08	0.001
Sex (1= women, 0= men)	4.01	2.02 to 7.98	<0.001
Square-root urinary creatinine (mg/dl)	1.19	1.08 to 1.30	<0.001
Square-root urinary uromodulin ( $\mu$ g/ml)	0.74	0.60 to 0.90	0.002

*When accounting for urinary creatinine, age, and sex, urinary uromodulin was negatively associated with the presence of urinary nitrites.*





## Urinary Uromodulin and Risk of Urinary Tract Infections: The Cardiovascular Health Study

*Pranav S. Garimella, MD, MPH,<sup>1</sup> Traci M. Bartz, PhD,<sup>2</sup> Joachim H. Ix, MD, MAS,<sup>3</sup>  
Michel Chonchol, MD,<sup>4</sup> Michael G. Shlipak, MD, MPH,<sup>5</sup> Prasad Devarajan, MD,<sup>6</sup>  
Michael R. Bennett, PhD,<sup>6</sup> and Mark J. Sarnak, MD, MS<sup>1</sup>*

- **Prospective longitudinal cohort** study in 953 participants enrolled in the Cardiovascular Health Study.
- Predictive value of **urinary uromodulin on composite of outpatient UTI events** adjusted for age, race, sex, body mass index, diabetes, eGFR, UAE.
- Results: Persons in the highest quartile of uromodulin concentration had a significantly lower risk for the composite outcome (incidence rate ratio [IRR], 0.47; 95% CI, 0.29-0.79) compared with those in the lowest quartile.
- Conclusions: **High urinary uromodulin levels are associated with lower risk for UTI** in older community-dwelling adults independent of traditional UTI risk factors.



## Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials



eGFR decline in 538 ADPKD patients from Mayo, with TKV imaging

# Mayo Classification Score


## CLASSIFICATION OF TYPICAL ADPKD CALCULATOR

- Total kidney volume: mL
- Height: m
- Age: yrs


→ *Height-adjusted TKV*

→ *ADPKD classification*

# The Mayo Clinic classification




- Rare kidney diseases: > 200 disorders (very rare to ADPKD)
- Overall prevalence: ~60-80 cases per 100,000
- At least 10% adults and virtually all children on RRT



# Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

- Patient-derived organoids (PDOs) emerged as robust preclinical models.
- Biobank of PDOs from metastatic colorectal and gastroesophageal cancer patients in phase 1/2 clinical trials.
- Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors.
- Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses.

***Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.***



# GWAS: CKD-defining Traits

---

- >20 GWAS on CKD-defining traits (eGFR<sub>crea</sub>, UACR)  
incl. 2 on renal function decline
- >60 loci associated with CKD-defining traits (eGFR<sub>cre</sub> – European ancestry)
- Most recent GWAS of kidney function: 11 million SNPs (imputed)

*But:*

- \* *Modest effect size*
- \* *Very small fraction of variance explained*
- \* *Biological relevance ?*



# GWAS: Concept

---


*Complex diseases (CKD, hypertension, diabetes, ...) are underlined by a number of common genetic variants, present in >1% of the population*

- Conceptual simplicity of GWAS:
  - 10 millions SNPs over the 3 billions bp – not random distribution
  - Linkage disequilibrium blocks – tag SNPs
  - Association tests between SNPs and given trait in large populations
  - Expansion of the coverage using genetic imputation (e.g. 1000 Genomes)

Thousands of loci associated with complex disorders and biomarkers  
Hypothesis-free, unbiased approach



# Prognostic Value of Uromodulin ?



## *Production in TAL*

- Handling of NaCl:
  - Blood pressure
  - Loop diuretics
- Handling of Ca<sup>2+</sup> & Mg<sup>2+</sup>:

## *Transgenic Mouse Models to Mimic Human Situation*






Wild-type *Umod*  
«protective» variant

Transgenic *Umod*  
«deleterious» variant

*Clinical studies in human cohorts - known UMOD genotype*

# Uromodulin Overexpression: NaCl-sensitive Hypertension



Tg *Umod* Mice



# Serum uromodulin—a marker of kidney function and renal parenchymal integrity

Nephrol Dial Transplant (2017) 1–12  
doi: 10.1093/ndt/gfw422

Jürgen E. Scherberich<sup>1</sup>, Rudolf Gruber<sup>2</sup>, Wolfgang Andreas Nockher<sup>3</sup>, Erik Ilsø Christensen<sup>4</sup>, Hans Schmitt<sup>5</sup>, Victor Herbst<sup>6</sup>, Matthias Block<sup>6</sup>, Jürgen Kaden<sup>7</sup> and Wolfgang Schlumberger<sup>6</sup>




Uromodulin levels correlate with eGFR, and parallel renal function after transplantation

# Uromodulin Overexpression: Increased NKCC2 Activity

## Furosemide test

Cohort of subjects with hypertension – stratified for UMOD genotype



*Differential response to diuretics – depending on UMOD genotype*



Dominiczak, A. , Delles, C. and Padmanabhan, S.



University  
of Glasgow

Volume overload is a cause for uncontrolled hypertension and yet **loop diuretics** are rarely used in hypertension without edema, heart failure or chronic kidney disease.

**A prospective genotype directed trial of a long-acting loop diuretic, torasemide in uncontrolled hypertensive patients** to test the hypothesis that the high *UMOD* genotype patients are good responders to loop diuretics.


Precision medicine trial funded by the British Heart Foundation (CS.16/1/31878).



Peritoneal solute transport	Drain volume	Predicted long-term response to standard-dose CAPD or CCPD <sup>a</sup> after loss of residual renal function		Preferred dialysis prescription after loss of residual renal function
		ultrafiltration	dialysis	
High	low	poor	adequate	NIPD, DAPD <sup>b</sup>
High average	low average	adequate	adequate	standard-dose PD <sup>a</sup>
Low average	high average	good	adequate or inadequate <sup>c</sup>	standard-dose PD <sup>a</sup> high-dose PD <sup>d</sup>
Low	high	excellent	inadequate	high-dose PD <sup>d</sup> or hemodialysis <sup>e</sup>



<sup>a</sup> Standard-dose PD = Standard-dose CAPD or CCPD: standard-dose CAPD = CAPD with 7.5–9.0 liters of





## PET (peritoneal equilibration test) 2

<b>Transporter</b>	<b>Waste removal</b>	<b>Water removal</b>	<b>Best type of PD</b>
High	Fast	Poor	Frequent exchanges, short dwells – APD
Average	OK	OK	CAPD or APD
Slow	Slow	Good	CAPD, 5 exchanges daily + 1 exchange at night

# Disruption of a novel regulatory element in the erythroid-specific promoter of the human *PKLR* gene causes severe pyruvate kinase deficiency

Richard van Wijk, Wouter W. van Solinge, Claus Nerlov, Ernest Beutler, Terri Gelbart, Gert Rijksen, and Finn C. Nielsen

*Blood* 2003; 101: 1596-1602



**CTCTG, core binding motif of a regulatory element for PKLR**